GNova Biotech

GNova Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative targeted protein degradation (TPD) therapies. The company leverages its proprietary PROTAC (Proteolysis-Targeting Chimera) platform to design small molecules that harness the body's natural protein disposal system to eliminate disease-causing proteins. GNova's pipeline is primarily focused on oncology, with lead programs targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer. By addressing targets previously considered undruggable, GNova aims to provide next-generation treatments for patients with resistant or refractory cancers. The company maintains a strong R&D presence and is actively advancing multiple candidates through early-phase clinical trials.